Novo Nordisk Caps Insulin Prices in Settlement with Minnesota Attorney General
Novo Nordisk, a leading Danish pharmaceutical company, has agreed to cap insulin prices as part of a settlement with Minnesota’s attorney general, who accused the three largest insulin manufacturers of inflating the drug’s cost to astronomical levels. The settlement, filed Monday in a Newark, New Jersey federal court, follows similar agreements reached last year with Eli Lilly and French drugmaker Sanofi, according to Reuters.
Featured News
UK Competition Watchdog Probes Into OCS’s £3.1 Billion Mitie Deal
Nov 18, 2026 by
CPI
Booking to Challenge EU Court Ruling Blocking $1.79B Etraveli Deal
Nov 18, 2026 by
CPI
Newsmax Sues to Block Fox-Roku Integration After $22 Billion Deal
Nov 18, 2026 by
CPI
Tesla, Hertz and Uber Face Antitrust Suit Over $4.2B Electric-Vehicle Deal
Nov 18, 2026 by
CPI
Simpson Thacher Adds Five Partners to Litigation Practice
Nov 18, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Data Portability
Nov 12, 2026 by
CPI
Mandating Access to a Dominant Platform’s Inferred Data: A Two Scenario Diagnosis
Nov 12, 2026 by
Sean Ennis
Data Portability Between Individual Control and Data Sharing at Scale
Nov 12, 2026 by
Jasper van den Boom & Inge Graef
Information Also Wants to Be Expensive: Data Portability and the Open-Systems Creed
Nov 12, 2026 by
Justin (Gus) Hurwitz
Data Portability’s Cybersecurity Paradox: When Protecting Consumer Data Restricts Competition
Nov 12, 2026 by
Sasha Hondagneu-Messner